Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

Next Previous
Trial Profile

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Vitiligo
  • Focus Registrational; Therapeutic Use
  • Acronyms TRuE-V2
  • Sponsors Incyte Corporation

Most Recent Events

  • 16 Oct 2024 According to an Incyte Corporation media release, OPZELURA has received a Notice of Compliance from Health Canada for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. The approval was based on TRuE-V2 program.
  • 11 Oct 2023 According to an Incyte Corporation media release, results of a pooled analysis of long-term extension (LTE) data from the TRuE-V1 and TRuE-V2 studies were presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023.
  • 11 Oct 2023 Results of a pooled analysis of long-term extension (LTE) data from the TRuE-V1 and TRuE-V2 studies presented in an Incyte Corporation media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top